First AD

Second AD

Prostate Cancer

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Androgen Deprivation Therapy in Prostate Cancer and Cardiovascular Risk

OncLive News Network®

Cardio-Oncology in Prostate Cancer

ADT as Treatment in Metastatic Prostate Cancer

Burden of Cardiovascular Disease in Prostate Cancer

Challenges Associated with ADT in Prostate Cancer

Significance of GnRH Antagonists in Prostate Cancer

Reducing the Risk for Cardiovascular Events: PRONOUNCE

Androgens and Cardiovascular Events

Likelihood for Cardiovascular Events After ADT

Metabolic Aberrations Associated With ADT

Predicting Risk for Metabolic Aberrations and CV Events 

Managing Metabolic Aberrations and CV Events from ADT

Strategies for Preventing CV Events in Prostate Cancer

ADT and Cardiovascular Risk in Prostate Cancer: Q&A